Cidara Therapeutics, Inc.
CDTXDelisted Jan 7, 2026- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001610618
Cidara Therapeutics, Inc. was delisted on Jan 7, 2026; its insiders filed their last Form 4 on Jan 9, 2026; 255 institutions reported holding it in 13F filings for Q4 2025, worth $7.36B in total; 3 superinvestors held it, including Maverick Capital and Soros Fund Management.
13F holders, Q4 2025
Institutional positions in Cidara Therapeutics, Inc. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
CDTX is no longer listed, so this page shows Q4 2025. 13F filings for later quarters list far fewer holders.
- Institutional holders
- 255
- +84 vs. Q3 2025
- Shares held
- 33.3M
- +888.0K (+2.7%) vs. Q3 2025
- Total value
- $7.36B
- +$4.25B (+136.9%) vs. Q3 2025
- New holders
- 139
- 63 more added
- Sold out
- 55
- 46 more reduced
2 institutions that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CDTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 255 | $7.36B |
| Q3 2025 | 173 | $3.11B |
| Q2 2025 | 109 | $1.26B |
| Q1 2025 | 46 | $205.9M |
| Q4 2024 | 40 | $183.6M |
| Q3 2024 | 27 | $35.6M |
| Q2 2024 | 26 | $16.9M |
| Q1 2024 | 50 | $20.3M |
| Q4 2023 | 51 | $18.4M |
| Q3 2023 | 52 | $22.7M |
| Q2 2023 | 52 | $29.7M |
| Q1 2023 | 54 | $34.4M |
| Q4 2022 | 42 | $20.2M |
| Q3 2022 | 42 | $17.1M |
| Q2 2022 | 46 | $13.3M |
| Q1 2022 | 44 | $25.2M |
| Q4 2021 | 53 | $39.5M |
| Q3 2021 | 50 | $42.1M |
| Q2 2021 | 55 | $40.5M |
| Q1 2021 | 62 | $56.6M |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Cidara Therapeutics, Inc.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Atom Investors LP | 0 | $0 | 0.00% | −2,436−100.0% | Sold out |
| Scientech Research LLC | 0 | $0 | 0.00% | −2,335−100.0% | Sold out |
| Trifecta Capital Advisors, LLC | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |
| Avion Wealth | 0 | $0 | 0.00% | −250−100.0% | Sold out |
| LRI Investments, LLC | 0 | $0 | 0.00% | −55−100.0% | Sold out |
| Grove Bank & Trust | 0 | $0 | 0.00% | −33−100.0% | Sold out |
| Principal Securities, Inc. | 0 | $0 | 0.00% | −12−100.0% | Sold out |
| SRS Capital Advisors, Inc. | 0 | $0 | 0.00% | −9−100.0% | Sold out |
| J.Safra Asset Management Corp | 0 | $0 | 0.00% | −4−100.0% | Sold out |
| Tortoise Investment Management, LLC | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| AXA Investment Managers S.A. | – | – | – | – | Not filed |
| Bryce Point Capital, LLC | – | – | – | – | Not filed |